Skip to main content

Table 1 Summary of patient characteristics at baseline in studies 3.1 and 3.5

From: Comparative efficacy of subcutaneous (CT-P13) and intravenous infliximab in adult patients with rheumatoid arthritis: a network meta-regression of individual patient data from two randomised trials

Variable Study 3.1 Study 3.5
Reference IFX IV (n = 304) CT-P13 IV (n = 302) All (n = 606) CT-P13 IV (n = 176) CT-P13 SC (n = 167) All (n = 343)
Demographics
 Sex Male, n (%) 48 (15.8%) 57 (18.9%) 105 (17.3%) 37 (21.0%) 37 (22.2%) 74 (21.6%)
Female, n (%) 256 (84.2%) 245 (81.1%) 501 (82.7%) 139 (79.0%) 130 (77.8%) 269 (78.4%)
 Race White, n (%) 222 (73.0%) 220 (72.8%) 442 (72.9%) 151 (85.8%) 145 (86.8%) 296 (86.3%)
Asian, n (%) 37 (12.2%) 34 (11.3%) 71 (11.7%) 2 (1.1%) 1 (0.6%) 3 (0.9%)
Black, n (%) 1 (0.3%) 2 (0.7%) 3 (0.5%)
Other, n (%) 44 (14.5%) 46 (15.2%) 90 (14.9%) 23 (13.1%) 21 (12.6%) 44 (12.8%)
 Region European, n (%) 199 (65.5%) 196 (64.9%) 395 (65.2%) 147 (83.5%) 141 (84.4%) 288 (84.0%)
Non-European, n (%) 105 (34.5%) 106 (35.1%) 211 (34.8%) 29 (16.5%) 26 (15.6%) 55 (16.0%)
 Age, years Mean ± SD 48.6 ± 11.5 49.0 ± 12.2 48.8 ± 11.8 51.9 ± 12.4 50.9 ± 12.2 51.4 ± 12.3
 Baseline weight, kg Mean ± SD 69.9 ± 15.8 70.7 ± 16.3 70.3 ± 16.0 72.7 ± 14.4 73.0 ± 15.1 72.9 ± 14.7
 Baseline BMI, kg/m2 Mean ± SD 26.3 ± 5.3 26.5 ± 5.3 26.4 ± 5.3 26.8 ± 4.1 26.8 ± 4.4 26.8 ± 4.3
Clinical characteristics
 CRP, mg/L Mean ± SD 18.9 ± 21.8 19.0 ± 25.1 18.9 ± 23.5 22.4 ± 35.4 18.3 ± 23.7 20.4 ± 30.2
 ESR, mm/h Mean ± SD 48.5 ± 22.6 46.5 ± 22.3 47.5 ± 22.4 44.6 ± 23.5 41.8 ± 19.1 43.2 ± 21.5
 DAS28-CRP Mean ± SD 5.8 ± 0.9 5.9 ± 0.8 5.8 ± 0.9 5.9 ± 0.8 6.0 ± 0.8 5.9 ± 0.8
 DAS28-ESR Mean ± SD 6.6 ± 0.8 6.7 ± 0.8 6.6 ± 0.8 6.6 ± 0.8 6.7 ± 0.8 6.6 ± 0.8
 CDAI Mean ± SD 39.4 ± 11.0 40.9 ± 11.4 40.2 ± 11.2 39.6 ± 10.0 42.7 ± 10.2 41.1 ± 10.2
 SDAI Mean ± SD 41.3 ± 11.6 42.8 ± 11.9 42.1 ± 11.8 41.9 ± 11.1 44.5 ± 10.7 43.1 ± 11.0
 SF-36 Mental Mean ± SD 37.8 ± 11.1 36.8 ± 10.7 37.3 ± 10.9 39.6 ± 10.5 39.9 ± 10.3 39.8 ± 10.4
 SF-36 Physical Mean ± SD 31.9 ± 7.2 31.1 ± 6.1 31.5 ± 6.7 33.3 ± 6.3 33.6 ± 5.6 33.5 ± 6.0
 Patient assessment of global disease activity Mean ± SD 65.4 ± 17.0 65.8 ± 17.2 65.6 ± 17.1 69.0 ± 17.5 70.5 ± 15.8 69.7 ± 16.7
 Physician assessment of global disease activity Mean ± SD 65.0 ± 13.5 64.9 ± 14.2 64.9 ± 13.8 68.9 ± 15.2 70.5 ± 14.1 69.7 ± 14.7
 HAQ-DI Mean ± SD 1.6 ± 0.6 1.6 ± 0.5 1.6 ± 0.6 1.6 ± 0.6 1.6 ± 0.5 1.6 ± 0.6
  1. BMI body mass index, CDAI Clinical Disease Activity Index, CRP C-reactive protein, DAS28-CRP 28-joint Disease Activity Score based on C-reactive protein, DAS28-ESR 28-joint Disease Activity Score based on erythrocyte sedimentation rate, ESR erythrocyte sedimentation rate, HAQ-DI Health Assessment Questionnaire–Disability Index, IFX infliximab, IV intravenous, SC subcutaneous, SDAI Simplified Disease Activity Index, SD standard deviation